Literature DB >> 17395343

Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease.

J P Harris1, M Jit, D Cooper, W J Edmunds.   

Abstract

Rotavirus is a major cause of gastroenteritis in young children. New vaccines for rotavirus are now available and countries need to establish the health and economic burden of rotavirus disease to assess whether vaccine introduction is advisable. This study assesses the fraction of acute gastroenteritis in children under 5 years that may be attributable to rotavirus using multiple linear regression. Results suggest around 45% of hospitalisations, 25% of GP consultations, 27% of NHS Direct calls and 20% of accident and emergency (A&E) attendances for acute gastroenteritis in this age group may be attributable to rotavirus. The annual incidence is estimated to be 4.5 hospitalisations, 9.3 A&E consultations, and 28-44 GP consultations per 1000 children under five years of age. The cost to the health service is estimated to be pound 14.2m per annum. Rotavirus vaccination has the potential to reduce this burden of disease. This study provides a sound basis on which to make this assessment and serves as a baseline against which any reductions that do occur if vaccination is introduced can be measured against.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17395343     DOI: 10.1016/j.vaccine.2007.02.072

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective.

Authors:  Emily R Smith; Emily E Rowlinson; Volga Iniguez; Kizee A Etienne; Rosario Rivera; Nataniel Mamani; Rick Rheingans; Maritza Patzi; Percy Halkyer; Juan S Leon
Journal:  Vaccine       Date:  2011-09-02       Impact factor: 3.641

Review 2.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

3.  Introduction of a new Rotavirus vaccine: Initial results of uptake and impact on laboratory confirmed cases in Anglia and Essex, United Kingdom, July 2015.

Authors:  Thomas Inns; Amy Trindall; Sara Dunling-Hall; Ananda Giri Shankar
Journal:  Hum Vaccin Immunother       Date:  2015-11-30       Impact factor: 3.452

4.  The Economic Value of Vaccination: Why Prevention is Wealth.

Authors: 
Journal:  J Mark Access Health Policy       Date:  2015-08-12

5.  Disease burden of rotavirus gastroenteritis in children up to 5 years of age in two Swiss cantons: paediatrician- and hospital-based surveillance.

Authors:  Laurence Lacroix; Annick Galetto-Lacour; Martin Altwegg; Konrad Egli; Martin Schmidt; Alain Gervaix
Journal:  Eur J Pediatr       Date:  2009-08-04       Impact factor: 3.183

6.  The health and economic burden of rotavirus disease in Belgium.

Authors:  Joke Bilcke; Pierre Van Damme; Frank De Smet; Germaine Hanquet; Marc Van Ranst; Philippe Beutels
Journal:  Eur J Pediatr       Date:  2008-03-04       Impact factor: 3.183

7.  Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination.

Authors:  Patricia Bruijning-Verhagen; Marie-Josée J Mangen; Mariet Felderhof; Nico G Hartwig; Marlies van Houten; Léon Winkel; Wouter J de Waal; Marc J M Bonten
Journal:  BMC Med       Date:  2013-04-26       Impact factor: 8.775

Review 8.  The UK immunisation schedule: changes to vaccine policy and practice in 2013/14.

Authors:  Christina J Atchison; Sondus Hassounah
Journal:  JRSM Open       Date:  2015-05-11

9.  Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data.

Authors:  Baudouin Standaert; Jorge A Gomez; Marc Raes; Serge Debrus; F Raúl Velázquez; Maarten J Postma
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

10.  Deaths from norovirus among the elderly, England and Wales.

Authors:  John P Harris; W John Edmunds; Richard Pebody; David W Brown; Ben A Lopman
Journal:  Emerg Infect Dis       Date:  2008-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.